Eli Lilly’s ramucirumab Ph III lung cancer trial meets primary endpoint

19 February 2014

US pharma major Eli Lilly (NYSE: LLY) has revealed that the REVEL trial showed that its ramucirumab improved survival in patients with non-small cell lung cancer (NSCLC), with the news pushing the firm’s shares up 3% to $57.00 in premarket trading.

According to analysts at Credit Suisse, ramucirumab could generate annual sales of $800 million by 2020, equal to around 4% of Lilly's revenues.

A global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line NSCLC showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm compared to the control arm of placebo plus docetaxel. The REVEL study also showed a statistically-significant improvement in progression-free survival in the ramucirumab arm compared to the control arm.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK